Търсене на изпитвания

AI · cancer

Намерени 1,748 изпитвания за "cancer" Стр. 54 от 88

Предстои набиране Фаза 2

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

Colon Cancer (Stage II &Amp; III) Immunotherapy Beta Blocker Neoadjuvant Chemoimmunotherapy

The goal of this prospective, single-center, multi-cohort clinical trial is to evaluate the efficacy and safety of neoadjuvant Iparomlimab/Tuvonralimab combined with CAPEOX, with or without propranolol, in patients with locally advanced pMMR (MSS) colon cancer. The main questions it aims to answer are: * What is the major pathological response (MPR) rate after neoadjuvant treatment and curative surgery (e.g., ≤10% viable tumor cells in the resected primary tumor)? * What are the key secondary outcomes (e.g., R0 resection rate, tumor regression grade, objective response rate, disease-free survival) and the safety/tolerability profile of these neoadjuvant regimens? If there is a comparison group: Researchers will compare Cohort A (Iparomlimab/Tuvonralimab + CAPEOX) versus Cohort B (Iparomlimab/Tuvonralimab + CAPEOX + propranolol) to see whether adding propranolol improves pathological and clinical responses while maintaining acceptable safety. Participants will: * Receive neoadjuvant Iparomlimab/Tuvonralimab + CAPEOX for a protocol-defined number of cycles, with or without propranolol depending on cohort assignment. * Undergo curative-intent surgical resection after completing neoadjuvant therapy. * Be followed for postoperative treatment, adverse events, and longer-term outcomes (e.g., recurrence and survival), and may contribute tumor/blood samples for exploratory biomarker analyses related to treatment response.

Начало: 20.04.2026 Край: 31.12.2026 Възраст: 18–75 г.

Sun Yat-sen University NCT07549906

Предстои набиране

Verification of Range Accuracy and Correlation With Clinical Toxicity Using Offline PET/CT for Hypofractionated Proton Radiotherapy in Breast Cancer

Breast Cancer

This is a single-arm, single-center, prospective observational study. It uses offline PET/CT to verify and quantify the range accuracy of hypofractionated proton radiotherapy for postoperative breast cancer. The correlation between range error and clinical toxicities (radiation pneumonitis, rib fracture) will be analyzed. A PET signal-proton range correlation model will be established using Monte Carlo simulation to provide evidence for optimizing proton therapy planning.

Начало: 16.04.2026 Край: 31.08.2028 Възраст: от 18 г.

Ruijin Hospital NCT07543107

Предстои набиране Фаза 1/2

ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer

This is a single-arm, multicenter, phase II study designed to evaluate the efficacy and safety of MRG003, an anti-EGFR antibody-drug conjugate, in combination with QL1706, a PD-1/CTLA-4 bispecific antibody, in patients with recurrent or metastatic cervical cancer who have failed prior platinum-based therapy.

Начало: 10.04.2026 Край: 31.03.2030 Възраст: от 18 г.

Second Affiliated Hospital, School of Medicine, Zhejian NCT07542717

Предстои набиране Фаза 1/2

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

Metastatic Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 delivered by different methods. The study is also further split into 2 parts, Part A which will test different dose levels and dosing schedules of AZD8359 to determine which doses are the best in terms of safety and side effects (dose escalation), and Part B will further test at least two AZD8359 doses in a larger group of participants (dose expansion).

Начало: 09.04.2026 Край: 11.10.2027 Възраст: 18–100 г. Лечение

Australia, South Korea, United States AstraZeneca NCT07529717

Предстои набиране Фаза 2

Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer

NSCLC

Major objectives to evaluate the efficacy and safety of lparomlimab and Tuvonralimab Injection ((QL1706, an Anti-PD-1/CTLA-4 Combined Antibody)) combined with SBRT in patients with early-stage non-small cell lung cancer.

Начало: 01.04.2026 Край: 31.01.2031 Възраст: от 18 г.

China Tianjin Medical University Cancer Institute and Hospita NCT07379398

Предстои набиране Фаза 3

A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)

Extensive-stage Small-cell Lung Cancer

This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with tislelizumab in first-line patients with extensive-stage small cell lung cancer.

Начало: 01.04.2026 Край: 01.12.2029 Възраст: от 18 г.

China Sichuan Baili Pharmaceutical Co., Ltd. NCT07502300

Предстои набиране

Feasibility and Acceptability of Wearable Sensors and ePROs in Early Phase Clinical Trials

Cancer

Wearable sensors offer opportunities to improve the people's experiences with cancer treatment and to improve care delivery. This is a single-arm, prospective, unblinded pilot study designed to evaluate the feasibility and acceptability of wearable sensor-based monitoring and incorporating electronic patient-reported outcomes (ePROs) in Phase I oncology clinical trials. The study will enroll participants enrolled in early phase clinical trials at the Cleveland Clinic Novel Therapeutics Clinic and aims to establish the foundation for future, larger-scale prospective studies integrating digital health technologies into early-phase cancer clinical trials. Participants will be offered a smartwatch device compatible to their phone's operating system and be guided through the installation and use of the researchers' free study mobile application. Participants already owning compatible smartwatch devices may elect to use their own smartwatch for the study.

Начало: 01.04.2026 Край: 01.01.2027 Възраст: от 18 г.

United States Case Comprehensive Cancer Center NCT07541365

Предстои набиране

Proton vs Photon IMRT Toxicity in Breast Cancer

Breast Cancer

This study aims to compare the differences in acute and long-term toxicities between intensity-modulated proton therapy (IMPT) and intensity-modulated photon radiotherapy (IMRT/VMAT) in postoperative breast cancer patients, with a focus on evaluating their impact on critical organs, including the heart, lungs, skin, esophagus, thyroid, and lymphatic tissues. Eligible patients will be followed for at least one year to assess the incidence and severity of both acute and late toxicities, as well as differences in patient-reported outcomes (PROs), cosmetic outcomes following breast-conserving surgery, and overall quality of life.

Начало: 01.04.2026 Край: 01.12.2027 Възраст: от 18 г.

China Ruijin Hospital NCT07537712

Предстои набиране

A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer (Prostate 007)

Prostate Cancer Hot Flashes

The purpose of this study is to find out if patients with prostate cancer who have vasomotor symptoms, commonly called hot flashes, from their Androgen Deprivation Therapy (ADT) will consistently wear a smartwatch device to track their health data, log hot flashes on their smartwatch, and how these data compare with daily surveys about their hot flashes. Participants will be asked to wear the smartwatch for 4 weeks and to log their hot flashes on their smart watch pressing a button on the watch. Participants will be asked to complete surveys (sent through a text message link) to describe their experiences with hot flashes.

Начало: 01.04.2026 Край: 01.05.2027 Възраст: от 18 г.

United States University of Virginia NCT07535541

Предстои набиране

Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma

Upper Tract Urothelial Carcinoma Receiving Kidney-sparing Therapy Upper Tract Urothelial Carcinoma

UTUC is a cancer that develops in the lining of the kidney or ureter. The standard treatment is radical nephroureterectomy, which removes the kidney and ureter. Although this surgery can control the cancer, it permanently reduces kidney function. Endoscopic treatment can serve as a kidney-sparing approach for low-risk UTUC; however, in high-risk patients, the high rate of upper tract local recurrence after endoscopic treatment remains the primary failure pattern. This study aims to evaluate the efficacy and safety of radiotherapy-involved kidney-sparing treatment for UTUC. The main questions this study aims to answer are: Can this multimodal kidney-sparing strategy reduce local recurrence of UTUC compared with endoscopic treatment alone? Participants in the kidney-sparing group will: Undergo endoscopic surgery to remove the tumor; Receive systemic therapy with disitamab vedotin and toripalimab; Receive targeted radiotherapy after surgery. Participants will undergo regular follow-up visits, including imaging examinations and endoscopic evaluations, to monitor for recurrence or disease progression. The results of this study may help determine whether a multimodal kidney-sparing treatment strategy could become a safe and effective option for selected patients with high-risk UTUC.

Начало: 01.04.2026 Край: 01.04.2030 Възраст: от 18 г.

China Peking University First Hospital NCT07504939

Предстои набиране

Comparison of Serratus Posterior Superior Intercostal Plane Block and Rhomboid Intercostal Block for Postoperative Analgesia Following Breast Cancer Surgery With Axillary Lymph Node Dissection

Breast Cancer Lymph Node Dissection Postoperative Pain Mastectomy

This randomized clinical trial aims to evaluate and compare the analgesic efficacy of the Serratus Posterior Superior Intercostal Plane (SPSIP) and Rhomboid Intercostal Block in patients undergoing Breast Cancer Surgery With Axillary Lymph Node Dissection. The primary outcome is Visual Analog Scale (VAS) during the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection), Patient satisfaction assessed using a Likert scale, quality of recovery assessed using the QoR-15 questionnaire.

Начало: 30.03.2026 Край: 30.04.2027 Възраст: 18–65 г.

Antalya City Hospital NCT07536867

Предстои набиране

Self-management Interventions to Reduce Cardiovascular Risks in Breast Cancer Survivors

Breast Cancer

The goal of this proposed single-group pre-post pilot study is to assess the feasibility and acceptability of the codesigned Nurse-led and GP-supported self-management interventions (NGPS) to reduce cardiovascular risks in breast cancer survivors with cardiovascular diseases. The study will also assess the preliminary effects of the NGPS intervention on various outcomes, such as behavioural, physiological, psychological, and healthcare usage. These outcomes will be measured at three time points, which include the baseline measurement at recruitment (T1-week 1), right after the four weeks' intervention (T2-week 4), and eight weeks after completing the intervention (T3-week 12). The study will be conducted in the primary care centres, and the self-management interventions are behavioural change interventions such as physical activity, diet modifications, tobacco cessation, weight management, eliminating or reducing alcohol consumption, and mind-body exercises such as yoga. The main questions it aims to answer are: 1. What are the recruitment, retention, attrition, and completion rates of participants and potential adverse effects related to the NGPS interventions for the participants throughout the pilot study? 2. What are the adherence rates of the NGPS protocol, participants' response and completion rates of the study instruments during the data collection period of the pilot study? 3. Do this pilot study results indicate any significant differences in cardiovascular health outcomes (e.g., BMI and blood pressure), physical activity, dietary intake, QoL, self-efficacy, anxiety and depression between and across different time points (Baseline (T1), post-intervention (T2), follow-up (T3))?

Начало: 01.03.2026 Край: 01.02.2027 Възраст: от 18 г. Поддържаща грижа

Australia University of Southern Queensland NCT07313397

Предстои набиране

GDF-15 and Its Relationship With Treatment-related ADverse Events in Breast Cancer

Breast Cancer

GRADE is trying to find out if there is a link between a hormone called GDF-15 and the side effects that people can experience when taking T-DXd. GDF-15 can be measured in the blood. GDF-15 levels in the blood will go up when the body is stressed under certain conditions, including breast cancer. There is a link between high GDF-15 levels and the nausea and vomiting experienced with "morning sickness" in pregnancy. It has also been shown that GDF-15 levels will go up with the use of other types of chemotherapy that are known to cause nausea and vomiting. Side effects such as feeling sick (nausea), vomiting and weight loss are common with T-DXd. Sometimes, these can be so severe that treatment needs to be stopped early. The investigators can't predict who will get bad side effects and who will not. If the investigators can find out if there is a link between GDF-15 and the side effects of T-DXd, they can use this information in future clinical trials.

Начало: 01.03.2026 Край: 01.09.2028 Възраст: от 18 г. Поддържаща грижа

Australia, Japan, United States Breast Cancer Trials, Australia and New Zealand NCT07465172

Предстои набиране Фаза 1

A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.

Imaging Colorectal Cancer Head and Neck Squamous Cell Carcinoma Non-Small Cell Lung Cancer +1

LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor (TGF) - β-driven biomarker expressed on the cell membrane of cancer cells and/or cancer-associated fibroblasts 9CAFs) in select tumor types. Upon binding, LNTH-2403 is rapidly internalized, such that it can serve as a dual-purpose agent for both non-invasive imaging and radiotheranostic treatment of LRRC15- positive tumors. This first-in-human (FIH) imaging study will evaluate the safety and imaging of LNTH-2403 in participants with locally advanced or metastatic solid tumors.

Начало: 30.01.2026 Край: 31.10.2027 Възраст: от 18 г. Диагностика

Australia Radiopharm Theranostics, Ltd NCT07272642

Предстои набиране Фаза 1/2

A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs

Prostate Cancer

ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer. The trial evaluates safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib.

Начало: 05.01.2026 Край: 04.01.2029 Възраст: от 18 г. Лечение

Australia, Canada, Japan +1 AstraZeneca NCT07336446

Предстои набиране Фаза 1

Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

This phase 1b trial is designed to evaluate the safety and tolerability of olaparib in combination with 177Lutetium-Prostate Specific Membrane Antigen (177 Lu-PSMA) and pembrolizumab in patients with metastatic castration resistant prostate cancer (mCRPC).

Начало: 01.11.2025 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT07090369

Предстои набиране

Home-Based Photo-Biomodulation for Management of Lymphoedema and Radiation Fibrosis in Patients After Head and Neck Cancer: A Single-Arm Feasibility Trial

Head and Neck Cancer

This feasibility trial will test the use of photo-biomodulation (PBM) therapy, predominantly self-delivered in the patient's home for 12-weeks, following completion of radiotherapy treatment for head and neck cancer. The primary objective is to establish feasibility of recruitment (uptake). Secondary objectives are to assess safety, additional elements of feasibility (adherence to the intervention, return of the device and attrition at the 3-month follow-up appointment) and acceptability of the trial to patients. Secondary measures will be performed to assess trends in effects of the intervention (pre-post intervention, within-group measures) for managing lymphoedema and radiation fibrosis.

Начало: 04.09.2025 Край: 31.10.2026 Поддържаща грижа

Australia Peter MacCallum Cancer Centre, Australia NCT07139782

Предстои набиране Фаза 3

Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy

Lung Cancer

This research project is testing a new treatment planning method for patients with lung cancer who will be treated with radiation therapy. This new method is called Computed Tomography (CT) ventilation imaging. It aims to help protect the healthiest parts of patient's lungs from being injured by the radiation therapy. The investigators will determine whether healthy lung sparing can improve the quality of life in these patients.

Начало: 01.05.2025 Край: 01.12.2028 Възраст: от 18 г. Друго

Australia University of Sydney NCT06127654

Предстои набиране

SunBeast: Evaluating UV Protective Behaviors and Education Interventions Among Ultrarunners

Sun Protection

Participants will be randomly assigned to either the intervention or control group using concealed allocation. The intervention-comprising targeted educational materials and behavioral prompts-will be delivered over three months preceding race day. All study participants will be required to complete the pre-race survey prior to the intervention. The intervention group will complete the SunBeast Educational module once and receive monthly reinforcement messages leading into race day. The SunBeast Educational Program module consists of a 30-minute live, interactive online discussion and infographics/videos on skin cancer, UV index awareness, sunscreen use, protective clothing, and timing of runs. The control group will receive a general wellness brochure via email. The general wellness brochure will contain UV protection information but will also have other general wellness topics.

Начало: 01.05.2027 Край: 01.05.2027 Възраст: от 18 г.

United States University of Michigan Rogel Cancer Center NCT07481344

Предстои набиране

Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy

Metastatic Bladder Cancer Peripheral Neuropathy Advanced Urothelial Cancer Metastatic Urothelial Cancer

The goal of this study is to evaluate the feasibility and preliminary efficacy of a combined acupuncture and exercise intervention for the management of chemotherapy-induced peripheral neuropathy (CIPN) in participants with metastatic bladder cancer receiving enfortumab vedotin (EV) and pembrolizumab (Pembro). The names of the two study groups in this research study are: * Acupuncture + Virtual Exercise (AVE) * Virtual Exercise Only (VE)

Начало: 02.10.2026 Край: 02.03.2027 Възраст: от 18 г.

United States Dana-Farber Cancer Institute NCT07548476

1 … 52 53 54 55 56 … 88